NCT07911579
A Study of SYH2051 in Combination With Irinotecan Hydrochloride Liposome Injection in Subjects With Advanced Solid Tumors
StatusNot Yet Recruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
DLT
Timeframe: From Day 1 to Day 28
Frequency and severity of AE
Timeframe: From Day 1 to 12 months.
Maximal tolerable dose (MTD)
Timeframe: From Day 1 to 12 months.
Recommended phase 2 dose (RP2D)
Timeframe: From Day 1 to 12 months.
ORR
Timeframe: From Day 1 to 12 months.
Secondary (5)
Cmax
AUCss,
ORR
PFS
OS
Arms and interventions
SYH2051 in combination with Irinotecan Hydrochloride Liposome.Experimental
Drugs: SYH2051, Irinotecan Hydrochloride Liposome.
Sites
1 site in 1 country
- Tianjin Medical University Cancer Institute & HospitalTianjin, Tianjin Municipality, China